During the past decade, National Cancer Center conducted 305 clinical trials. In the 10-year time frame, 305 clinical trials started and 87 clinical trials were completed, i.e. on average, 28.5% percent of trials that started reached the finish line to date. In the past 5 years, 147 clinical trials started and 61 clinical trials were completed. i.e. 41.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Center" #1 sponsor was "National Cancer Center, Korea" with 128 trials, followed by "Hoffmann-La Roche" with 51 trials sponsored, "Janssen Research & Development, LLC" with 20 trials sponsored, "Pfizer" with 17 trials sponsored and "BeiGene" with 17 trials sponsored. Other sponsors include 235 different institutions and companies that sponsored additional 127 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 13 trials as a collaborator, "Seoul National University Bundang Hospital" with 13 trials as a collaborator, "Seoul National University Hospital" with 13 trials as a collaborator, "AstraZeneca" with 12 trials as a collaborator and "Asan Medical Center" with 11 trials as a collaborator. Other collaborators include 258 different institutions and companies that were collaborators in the rest 156 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Center" are "Breast Cancer" (38 trials), "Gastric Cancer" (20 trials), "Metastatic Breast Cancer" (13 trials), "Non-Small Cell Lung Cancer" (13 trials) and "Breast Neoplasms" (12 trials). Many other conditions were trialed in "National Cancer Center" in a lesser frequency.

Most popular intervention types in "National Cancer Center" are "Drug" (372 trials), "Procedure" (43 trials), "Other" (31 trials), "Radiation" (29 trials) and "Biological" (22 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (57 trials), "Paclitaxel" (29 trials), "Atezolizumab" (25 trials), "Carboplatin" (24 trials) and "Cisplatin" (19 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Center" are 379 trials for "All" genders, 69 trials for "Female" genders and 18 trials for "Male" genders.

Currently, there are NaN active trials in "National Cancer Center". undefined are not yet recruiting, 100 are recruiting, 99 are Active, not recruiting, and 7 are Enrolling by invitation. In total, there were 158 completed trials in National Cancer Center, undefined suspended trials, and 32 terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Center, 66 "Phase 1" clinical trials were conducted, 192 "Phase 2" clinical trials and 181 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 27 trials that are defined as “Not Applicable".

National Cancer Center has several departments that took part in Clinical trials: "Clinical Trial Pharmacy, National Cancer Center" - 4 trials, "National Cancer Center, Center for Breast Cancer" - 3 trials, "Center for Liver Cancer, National Cancer Center" - 2 trials, "Respiratory Clinic, National Cancer Center" - 2 trials